We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Childhood Liver Cancer "Signatures" May Help Predict Response to Chemo

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Childhood Liver Cancer "Signatures" May Help Predict Response to Chemo"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

A new UC San Francisco study sheds light on the diversity within the most common type of pediatric liver tumor and suggests a way forward for more precise chemotherapy treatment.

The study, publishing in Nature Communications on August 25, used single-cell transcriptomic techniques to analyze hepatoblastoma specimens from infants and children under age four. From nine samples, the researchers identified five hepatoblastoma tumor signatures that may account for the heterogeneity in this cancer, and that may predict responses to chemotherapy treatments.

“Many pediatric tumors originate from an embryonic cell and some are bland in terms of their mutational burden,” said study co-author Amar Nijagal, assistant professor in the Division of Pediatric Surgery at UCSF Benioff Children’s Hospital, San Francisco. “The fact that this tumor has significant heterogeneity made us question what was driving this heterogeneity, and we wanted to learn more.”

Researchers from three different labs at UCSF worked on the study, combining expertise in pediatric surgery, hepatology, and genomics, which facilitated the rare opportunity to analyze tumors directly from the operating room, Nijagal said.

“With this combined expertise in one place at UCSF, we can foresee a situation in which a child presents with a liver tumor; we biopsy it; we understand its tumor signatures; we grow and test therapeutics in a petri dish; and we use what we find to treat the patient,” Nijagal said.

Aside from offering hope for better treatment, studying hepatoblastoma provides a window into how tissues develop normally, Nijagal said.

“Normal development and cancer are two sides of the same coin,” Nijagal said. “Here you have a tumor that is not acquired, as many adult tumors are from something like smoking or excess UV exposure. Instead, something goes wrong during development to set off these hepatoblasts towards developing into a malignancy. So we are interested in learning what are the signals – such as those from immune cells – that maintain normal development."

Reference: Song H, Bucher S, Rosenberg K, et al. Single-cell analysis of hepatoblastoma identifies tumor signatures that predict chemotherapy susceptibility using patient-specific tumor spheroids. Nat Commun. 2022;13(1):4878. doi: 10.1038/s41467-022-32473-z

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.